Profile data is unavailable for this security.
About the company
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
- Revenue in USD (TTM)312.78m
- Net income in USD-143.56m
- Incorporated1998
- Employees635.00
- LocationCareDx Inc8000 Marina Blvd, 4Th FloorBRISBANE 94005United StatesUSA
- Phone+1 (415) 287-2300
- Fax+1 (302) 636-5454
- Websitehttps://www.caredx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.08bn | 37.00 | -- | 183.07 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Gyre Therapeutics Inc | 191.34m | -76.96m | 1.10bn | 593.00 | -- | 15.95 | -- | 5.74 | -0.2281 | -0.2281 | 1.35 | 0.7366 | 2.83 | -- | 19.64 | 322,656.00 | -95.21 | -73.59 | -154.33 | -99.94 | 96.16 | -- | -33.64 | -205.62 | 3.29 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Pharvaris NV | 0.00 | -138.46m | 1.14bn | 82.00 | -- | 3.66 | -- | -- | -2.71 | -2.71 | 0.00 | 5.76 | 0.00 | -- | -- | 0.00 | -54.80 | -36.09 | -58.76 | -38.27 | -- | -- | -- | -- | -- | -41.69 | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -258.08m | 1.17bn | 268.00 | -- | 3.53 | -- | -- | -2.75 | -2.75 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -52.01 | -35.26 | -56.17 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0605 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Arcutis Biotherapeutics Inc | 138.71m | -195.54m | 1.20bn | 296.00 | -- | 7.65 | -- | 8.64 | -1.79 | -1.79 | 1.23 | 1.34 | 0.3799 | 1.04 | 3.49 | 468,608.10 | -53.55 | -65.64 | -75.79 | -71.72 | 89.57 | -- | -140.97 | -1,513.03 | 2.38 | -6.19 | 0.5664 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| CareDx Inc | 312.78m | -143.56m | 1.21bn | 635.00 | -- | 4.39 | -- | 3.87 | -2.70 | -2.70 | 5.95 | 5.15 | 0.6395 | 5.75 | 5.29 | 492,559.10 | -29.35 | -17.54 | -34.84 | -20.85 | 65.77 | 65.50 | -45.90 | -27.78 | 3.87 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Ardelyx Inc | 251.85m | -72.58m | 1.21bn | 267.00 | -- | 7.66 | -- | 4.82 | -0.3113 | -0.3113 | 1.08 | 0.6682 | 0.7664 | 3.76 | 5.22 | 943,254.70 | -22.09 | -46.14 | -26.72 | -57.32 | 85.16 | 88.15 | -28.82 | -240.87 | 3.87 | -5.94 | 0.3888 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Enliven Therapeutics Inc | 0.00 | -85.21m | 1.24bn | 57.00 | -- | 4.16 | -- | -- | -1.91 | -1.91 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -29.41 | -42.26 | -30.97 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Maravai Lifesciences Holdings Inc | 276.92m | -224.66m | 1.25bn | 580.00 | -- | 3.63 | -- | 4.52 | -1.65 | -1.65 | 2.04 | 1.37 | 0.1562 | 2.98 | 7.43 | 426,030.80 | -18.23 | 12.67 | -23.39 | 15.46 | 46.36 | 74.79 | -116.68 | 37.32 | 9.94 | -1.47 | 0.4746 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Aurinia Pharmaceuticals Inc | 220.36m | -22.55m | 1.26bn | 300.00 | -- | 3.23 | -- | 5.70 | -0.1582 | -0.1582 | 1.53 | 2.71 | 0.3991 | 0.7854 | 5.92 | 734,536.70 | -4.08 | -25.97 | -4.74 | -28.24 | 87.25 | -- | -10.23 | -137.64 | 5.11 | -- | 0.1725 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Novavax Inc | 885.19m | -284.86m | 1.29bn | 1.54k | -- | -- | -- | 1.45 | -2.26 | -2.26 | 6.00 | -3.29 | 0.5254 | 8.19 | 8.10 | 573,683.10 | -16.91 | -46.06 | -79.12 | -269.57 | 63.79 | -- | -32.18 | -75.94 | 0.9272 | -17.46 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| ARS Pharmaceuticals Inc | 2.57m | -49.10m | 1.30bn | 146.00 | -- | 6.47 | -- | 505.09 | -0.5076 | -0.5076 | 0.0266 | 2.07 | 0.011 | -- | -- | 107,000.00 | -21.07 | -20.37 | -22.40 | -21.32 | 76.17 | -- | -1,912.15 | -17,491.75 | 12.52 | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Arcus Biosciences Inc | 263.00m | -270.00m | 1.31bn | 577.00 | -- | 2.31 | -- | 4.97 | -3.15 | -3.15 | 3.06 | 6.17 | 0.2153 | -- | 6.83 | 455,805.90 | -22.10 | -15.85 | -26.63 | -18.25 | -- | -- | -102.66 | -103.46 | -- | -- | 0.0768 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Syndax Pharmaceuticals Inc | 16.00m | -297.06m | 1.33bn | 112.00 | -- | 3.64 | -- | 83.22 | -3.63 | -3.63 | 0.1949 | 4.28 | 0.0388 | -- | 3.60 | 142,857.10 | -72.01 | -27.90 | -81.78 | -30.15 | -- | -- | -1,856.64 | -324.34 | -- | -- | 0.00003 | -- | -- | -- | -40.19 | -- | -- | -- |
| Day One Biopharmaceuticals Inc | 101.95m | -84.29m | 1.35bn | 174.00 | -- | 2.42 | -- | 13.20 | -1.02 | -1.02 | 1.14 | 5.51 | 0.2009 | -- | -- | 657,761.30 | -16.61 | -- | -17.73 | -- | 97.75 | -- | -82.68 | -- | 14.55 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to CareDx Inc's reporting currency: US Dollar USD
47.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.44m | 8.41% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 4.35m | 8.25% |
| Bellevue Asset Management AGas of 30 Sep 2024 | 3.15m | 5.96% |
| ARK Investment Management LLCas of 30 Sep 2024 | 2.99m | 5.67% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.04m | 3.86% |
| BAMCO, Inc.as of 30 Sep 2024 | 1.88m | 3.56% |
| Nikko Asset Management Co., Ltd.as of 30 Sep 2024 | 1.65m | 3.14% |
| Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 1.65m | 3.13% |
| Fred Alger Management LLCas of 30 Sep 2024 | 1.50m | 2.85% |
| Gagnon Securities LLCas of 30 Sep 2024 | 1.44m | 2.73% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
